Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AKBANASDAQ:CVACNASDAQ:ELVNNASDAQ:INZY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKBAAkebia Therapeutics$3.68+3.4%$2.78$0.80▼$4.08$934.98M0.853.23 million shs9.32 million shsCVACCureVac$5.44-0.9%$4.02$2.37▼$5.72$1.23B2.49810,681 shs2.04 million shsELVNEnliven Therapeutics$21.30-1.3%$18.79$13.30▼$30.03$1.06B0.79293,457 shs518,501 shsINZYInozyme Pharma$3.99+0.3%$2.61$0.72▼$6.24$257.28M2.29890,088 shs771,612 shs10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKBAAkebia Therapeutics+3.37%+3.37%+30.96%+72.77%+264.36%CVACCureVac-0.91%-2.33%+39.49%+88.24%+67.38%ELVNEnliven Therapeutics-1.25%-2.78%+25.81%+1.04%+4.05%INZYInozyme Pharma+0.25%0.00%+1.01%+309.61%-9.32%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAKBAAkebia Therapeutics4.0816 of 5 stars3.62.00.04.03.50.80.6CVACCureVac4.5795 of 5 stars4.24.00.04.82.30.01.3ELVNEnliven Therapeutics2.6592 of 5 stars3.51.00.00.03.14.20.0INZYInozyme Pharma2.652 of 5 stars4.23.00.00.00.62.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKBAAkebia Therapeutics 3.20Buy$6.7583.42% UpsideCVACCureVac 2.40Hold$9.0065.44% UpsideELVNEnliven Therapeutics 3.00Buy$39.6085.92% UpsideINZYInozyme Pharma 2.44Hold$11.75194.49% UpsideCurrent Analyst Ratings BreakdownLatest INZY, AKBA, CVAC, and ELVN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/16/2025ELVNEnliven TherapeuticsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$40.00 ➝ $52.006/16/2025ELVNEnliven TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$37.006/13/2025CVACCureVacJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold$7.00 ➝ $5.006/12/2025CVACCureVacCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeMarket Perform6/12/2025CVACCureVacCitizens JmpSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold6/4/2025AKBAAkebia TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$8.005/28/2025CVACCureVacJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$10.005/16/2025ELVNEnliven TherapeuticsJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$36.00 ➝ $27.005/16/2025INZYInozyme PharmaTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/16/2025INZYInozyme PharmaWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/16/2025INZYInozyme PharmaNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeModerate Buy ➝ Hold(Data available from 6/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKBAAkebia Therapeutics$160.18M6.03N/AN/A($0.23) per share-16.00CVACCureVac$579.18M2.11$0.86 per share6.29$3.36 per share1.62ELVNEnliven TherapeuticsN/AN/AN/AN/A$6.34 per shareN/AINZYInozyme PharmaN/AN/AN/AN/A$0.90 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKBAAkebia Therapeutics-$69.41M-$0.21N/AN/AN/A-24.51%N/A-18.92%8/6/2025 (Estimated)CVACCureVac$175.50M$0.925.91N/AN/A35.44%30.89%25.54%8/13/2025 (Estimated)ELVNEnliven Therapeutics-$89.02M-$1.92N/AN/AN/AN/A-31.84%-30.09%8/12/2025 (Estimated)INZYInozyme Pharma-$102.02M-$1.69N/AN/AN/AN/A-159.93%-82.48%8/5/2025 (Estimated)Latest INZY, AKBA, CVAC, and ELVN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/22/2025Q1 2025CVACCureVac-$0.16-$0.24-$0.08-$0.24$4.27 million$0.94 million5/14/2025Q1 2025ELVNEnliven Therapeutics-$0.51-$0.57-$0.06-$0.57N/AN/A5/14/2025Q1 2025INZYInozyme Pharma-$0.43-$0.44-$0.01-$0.44N/AN/A5/8/2025Q1 2025AKBAAkebia Therapeutics-$0.03$0.03+$0.06$0.03$44.88 million$57.34 million4/10/2025Q4 2024CVACCureVac-$0.14-$0.15-$0.01-$0.15$6.40 million$15.44 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAKBAAkebia TherapeuticsN/AN/AN/AN/AN/ACVACCureVacN/AN/AN/AN/AN/AELVNEnliven TherapeuticsN/AN/AN/AN/AN/AINZYInozyme PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKBAAkebia Therapeutics1.892.232.02CVACCureVac0.057.657.64ELVNEnliven TherapeuticsN/A21.0721.06INZYInozyme Pharma0.652.192.19Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKBAAkebia Therapeutics33.92%CVACCureVac17.26%ELVNEnliven Therapeutics95.08%INZYInozyme Pharma88.30%Insider OwnershipCompanyInsider OwnershipAKBAAkebia Therapeutics3.00%CVACCureVac2.15%ELVNEnliven Therapeutics25.90%INZYInozyme Pharma12.18%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAKBAAkebia Therapeutics430262.64 million254.76 millionOptionableCVACCureVac880224.34 million219.52 millionOptionableELVNEnliven Therapeutics5049.07 million36.36 millionOptionableINZYInozyme Pharma5064.56 million56.70 millionOptionableINZY, AKBA, CVAC, and ELVN HeadlinesRecent News About These CompaniesInozyme Pharma, Inc. Announces Postponement of 2025 Annual Meeting of StockholdersJune 20 at 5:00 PM | globenewswire.comInozyme Pharma Reports Increased Loss Amid Strategic FocusJune 9, 2025 | tipranks.comInozyme Pharma, Inc. (NASDAQ:INZY) Receives Consensus Recommendation of "Hold" from BrokeragesJune 9, 2025 | marketbeat.comMillennium Management LLC Has $5.21 Million Stake in Inozyme Pharma, Inc. (NASDAQ:INZY)May 30, 2025 | marketbeat.comBMRN to Acquire Inozyme PharmaMay 22, 2025 | finance.yahoo.comINOZYME PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inozyme Pharma, Inc. - INZYMay 21, 2025 | businesswire.comStockWatch: With Inozyme Buyout, BioMarin Pursues Growth via M&AMay 18, 2025 | genengnews.comJefferies Downgrades Inozyme Pharma (INZY)May 17, 2025 | msn.comNeedham Downgrades Inozyme Pharma (INZY)May 17, 2025 | msn.comLeerink bullish on BioMarin following Inozyme deal, expects additional BDMay 17, 2025 | finance.yahoo.comInozyme Shares More Than Double in Surge Toward BioMarin's Buyout PriceMay 16, 2025 | marketwatch.comBioMarin to buy rare disease drugmaker Inozyme for $270MMay 16, 2025 | biopharmadive.comBioMarin stock rises following Inozyme Pharma acquisitionMay 16, 2025 | in.investing.comBioMarin to Acquire Inozyme Pharma for $270MMay 16, 2025 | contractpharma.comBioMarin buys Inozyme for $270 millionMay 16, 2025 | thepharmaletter.comBioMarin to buy enzyme therapy developer Inozyme in $270M all-cash dealMay 16, 2025 | msn.comInozyme Stock Rockets 179% After BioMarin Agrees To Acquire The Company For $270M: Retail Sentiment BrightensMay 16, 2025 | msn.comSHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Inozyme Pharma, Inc. - INZYMay 16, 2025 | prnewswire.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CHTR and INZY on Behalf of ShareholdersMay 16, 2025 | prnewswire.comINZY Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Inozyme Pharma, Inc. Is Fair to ShareholdersMay 16, 2025 | businesswire.comShareholder Alert: The Ademi Firm investigates whether Inozyme Pharma, Inc. is obtaining a Fair Price for its Public ShareholdersMay 16, 2025 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeINZY, AKBA, CVAC, and ELVN Company DescriptionsAkebia Therapeutics NASDAQ:AKBA$3.68 +0.12 (+3.37%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$3.68 -0.01 (-0.14%) As of 06/20/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.CureVac NASDAQ:CVAC$5.44 -0.05 (-0.91%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$5.44 -0.01 (-0.09%) As of 06/20/2025 05:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.Enliven Therapeutics NASDAQ:ELVN$21.30 -0.27 (-1.25%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$21.30 0.00 (0.00%) As of 06/20/2025 04:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.Inozyme Pharma NASDAQ:INZY$3.99 +0.01 (+0.25%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$3.99 0.00 (0.00%) As of 06/20/2025 06:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Inozyme Pharma, Inc., a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Robinhood Director Sells Millions, But HOOD Stock Eyes Gains Coinbase Stock Pops as Senate Passes GENIUS Stablecoin Bill Overheated Market? Analysts Watch These Red Flags Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
